Taxus launch in Japan
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific launches its Taxus Express2 paclitaxel-eluting stent in Japan May 8. The firm secured reimbursement from Japan's National Health Insurance System May 1 for the device, which gained Ministry of Health, Labor and Welfare approval in late March. Taxus joins Johnson & Johnson/Cordis' Cypher, the only drug-eluting stent on the Japanese market (1"The Gray Sheet" April 9, 2007, p. 17)...
You may also be interested in...
Boston Scientific’s Taxus Express2 To Make Long-Awaited Debut In Japan
Boston Scientific expects to launch its Taxus Express2 paclitaxel-eluting stent in Japan in four to six weeks, once the Japanese Ministry of Health, Labor and Welfare establishes reimbursement for the device
Irish Body Sets Out Five-Year Vision Strategy For Off-Patent Sector
With a focus on drug accessibility, supply chain resilience, and a balanced approach to sustainability, Medicines for Ireland “calls to action” with its five-year plan.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.